Multiresistant organisms: bacteria and beyond
- PMID: 35283468
- DOI: 10.1097/MOT.0000000000000976
Multiresistant organisms: bacteria and beyond
Abstract
Purpose of review: Infections with multiresistant organisms are an emerging problem, cause early mortality post lung transplantation and are sometimes associated with graft dysfunction. Frequently they raise questions about the selection of lung transplant candidates and therapeutic management post lung transplantation. There are no guidelines and management must be individualized. This review summarizes the available therapeutic options in cases of multidrug-resistant (MDR) organisms and outcomes after lung transplant.
Recent findings: Improvements in diagnosis, new and more effective drugs and the experience gained in the management of these infections in lung transplantation, lead to a more optimistic horizon than that found a decade ago.
Summary: Update on the management of Burkholderia cepacia complex, Mycobacterium abscessus complex, Aspergillus spp., Scedosporium spp. and Lomentospora prolificans infections. This review clarifies current posttransplant outcomes and adds a little hope in these scenarios.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Chambers DC, Perch M, Zuckermann A, et al. International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult lung transplantation report-2021; focus on recipient characteristics. J Heart Lung Transplant 2021; 40:1060–1072.
-
- Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34:1–15.
-
- Belperio JA, Glanville AR. Lung transplantation: controversies and evolving concepts. Semin Respir Crit Care Med 2018; 39:115–116.
-
- Skolnik K, Kirkpatrick G, Quon BS. Nontuberculous mycobacteria in cystic fibrosis. Curr Treat Options Infect Dis 2016; 8:259–274.
-
- Viviani L, Harrison MJ, Zolin A, et al. Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF). J Cyst Fibros 2016; 15:619–623.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
